市场活动

查看全部

    AACR 2023 posters

    April 23, 2023
    Share on:

    We're attending AACR 2023, held from April 14-19 in Orlando, Florida! For the latest advances, service offerings, and promotions, register now to visit our team at Booth 723, which will be open from April 16-19. Be sure to also visit our 25 posters, which can now be added to your AACR itinerary.

    Off-the-Shelf Mouse Model Posters

    TargetMouse modelPoster
    CCR8B-hPD-1/hPD-L1/hCCR8 miceA Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies
    CD94/NKG2AB-hCD94/hNKG2A miceB-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A
    MGMT3B-NDG MGMT3 miceDevelopment of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution
    MHC DKOB-NDG MHC I/II DKO mice plusDevelopment of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution
    TREM2B-hTREM2 miceGeneration of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages
    hOX40/Ox40L B-hOX40/hOX40L miceHumanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics
    hVEGFR2B-hVEGFR2 miceIn vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice
    hIL11RAB-hIL11RA miceIn vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage
    CD36B-hCD36 miceNovel Humanized CD36 Mouse Model for Therapeutic Studies

    RenMabTM-Based Fully Human Antibody Discovery Platforms

    PlatformPoster
    RenNano® TFR1Discovery of RenNano®-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier
    RenNano®RenNano® Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics
    TCR MimicTargeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived From HLA Transgenic RenMiceTM
    HiTS PlatformThe RenMiceTM HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets

    Fully Human Monoclonal Antibody Assets

    Antibody TargetPoster
    TNFR21C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity
    BCG008BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice
    IL2RAD02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice
    B7-H3*Novel Preclinical Candidates Targeting B7-H3, 6B5 and 10F7, Are Suitable for Development Into Various Drug Modalities

    RenLite®-derived Fully Human Bispecific ADC Assets

    Bispecific ADCPoster
    YH012A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy
    BSA01A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity
    BCG022BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET
    BCG033Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer

    The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. (Source: AACR)